Advanced

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)

Aus, G; Becker, Charlotte LU ; Lilja, Hans LU ; Khatami, A; Pihl, CG and Hugosson, J (2003) In Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00 37(6). p.466-470
Abstract
Objective: To evaluate whether the free-to-total prostate-specific antigen (F/T-PSA) ratio can be used to differentiate between stage pT2 and pT3 prostate cancer. Material and Methods: A total of 176 consecutive patients from the Goteborg Screening Study (median T-PSA 4.2 ng/ml) who underwent radical prostatectomy (without neoadjuvant hormonal therapy) were included in the study. The pT stage was correlated with classical risk factors such as T-PSA and Gleason sum and the impact of the F/T-PSA ratio was evaluated. Results: A total of 42/176 patients (23.9%) had stage pT3 prostate cancer. Patients with an F/T-PSA ratio in the lowest quartile (<10.7%) had extracapsular tumor growth in 46.5% of cases, compared to 16.7% for those with an... (More)
Objective: To evaluate whether the free-to-total prostate-specific antigen (F/T-PSA) ratio can be used to differentiate between stage pT2 and pT3 prostate cancer. Material and Methods: A total of 176 consecutive patients from the Goteborg Screening Study (median T-PSA 4.2 ng/ml) who underwent radical prostatectomy (without neoadjuvant hormonal therapy) were included in the study. The pT stage was correlated with classical risk factors such as T-PSA and Gleason sum and the impact of the F/T-PSA ratio was evaluated. Results: A total of 42/176 patients (23.9%) had stage pT3 prostate cancer. Patients with an F/T-PSA ratio in the lowest quartile (<10.7%) had extracapsular tumor growth in 46.5% of cases, compared to 16.7% for those with an F/T-PSA ratio >10.7% ( p = 0.0002). Patients with high-risk features (T-PSA >10 ng/ml or Gleason sum greater than or equal to7) had a high risk (54-60%) for stage pT3 prostate cancer. In low-risk patients, the subgroup with an F/T-PSA ratio <10.7% had a risk of 37.0%, compared to only 13.3% for those with a ratio of >10.7% (p = 0.0092). Conclusions: In patients with low-risk early-stage prostate cancer, the F/T-PSA ratio provides statistically significant, independent and clinically relevant preoperative information about the risk of extracapsular tumor growth. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
prostate cancer, extracapsular tumor growth, staging, prostate-specific antigen
in
Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00
volume
37
issue
6
pages
466 - 470
publisher
Taylor & Francis
external identifiers
  • wos:000187296700004
  • pmid:14675918
  • scopus:0347756691
ISSN
0036-5599
DOI
10.1080/00365590310001746
language
English
LU publication?
yes
id
29a1a7bf-ae48-48fe-a10b-5c981b9cb36e (old id 899574)
date added to LUP
2008-01-10 11:39:57
date last changed
2018-01-07 08:55:21
@article{29a1a7bf-ae48-48fe-a10b-5c981b9cb36e,
  abstract     = {Objective: To evaluate whether the free-to-total prostate-specific antigen (F/T-PSA) ratio can be used to differentiate between stage pT2 and pT3 prostate cancer. Material and Methods: A total of 176 consecutive patients from the Goteborg Screening Study (median T-PSA 4.2 ng/ml) who underwent radical prostatectomy (without neoadjuvant hormonal therapy) were included in the study. The pT stage was correlated with classical risk factors such as T-PSA and Gleason sum and the impact of the F/T-PSA ratio was evaluated. Results: A total of 42/176 patients (23.9%) had stage pT3 prostate cancer. Patients with an F/T-PSA ratio in the lowest quartile (&lt;10.7%) had extracapsular tumor growth in 46.5% of cases, compared to 16.7% for those with an F/T-PSA ratio &gt;10.7% ( p = 0.0002). Patients with high-risk features (T-PSA &gt;10 ng/ml or Gleason sum greater than or equal to7) had a high risk (54-60%) for stage pT3 prostate cancer. In low-risk patients, the subgroup with an F/T-PSA ratio &lt;10.7% had a risk of 37.0%, compared to only 13.3% for those with a ratio of &gt;10.7% (p = 0.0092). Conclusions: In patients with low-risk early-stage prostate cancer, the F/T-PSA ratio provides statistically significant, independent and clinically relevant preoperative information about the risk of extracapsular tumor growth.},
  author       = {Aus, G and Becker, Charlotte and Lilja, Hans and Khatami, A and Pihl, CG and Hugosson, J},
  issn         = {0036-5599},
  keyword      = {prostate cancer,extracapsular tumor growth,staging,prostate-specific antigen},
  language     = {eng},
  number       = {6},
  pages        = {466--470},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00},
  title        = {Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)},
  url          = {http://dx.doi.org/10.1080/00365590310001746},
  volume       = {37},
  year         = {2003},
}